Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma
about
Tumour T1 changes in vivo are highly predictive of response to chemotherapy and reflect the number of viable tumour cells--a preclinical MR study in mice.Quantitative evaluation of multi-parametric MR imaging marker changes post-laser interstitial ablation therapy (LITT) for epilepsy.Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastomaIdentifying MRI markers associated with early response following laser ablation for neurological disorders: preliminary findings.Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot studyCyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent NeuroblastomaMR Fingerprinting for Rapid Quantitative Abdominal Imaging.Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCNFunctional MRI and CT biomarkers in oncology.Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform.Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.
P2860
Q30757279-A98B9E89-DA9F-42B5-8929-28DE9CB0F476Q33959196-2FCDA262-5F10-40EF-A621-EFC04BA242ECQ35131527-38D58F13-A722-4DDA-BCA6-542E94FE67EEQ35517507-693CC623-9399-4DAC-8ACD-9E63D08978B7Q35670736-9910D28C-A2E8-43E1-BC5D-8090C6C26802Q35929346-1A8BFD5C-97C1-4C84-B4DC-CC23D61C0F7BQ36281460-D46A5377-22E2-4A4B-A3D4-0C7954F95555Q36762757-8F61C87A-273F-45F7-8DF6-ECD46C947AEFQ37182194-2BB3D04C-04FE-43D8-A0DE-AF4845D7A9B6Q37305906-DB671FF9-3E71-4753-93E1-88E0A24A77D3Q38314429-B985B61A-9B13-4157-B43D-59E5BAF0ECB9Q38634667-505A2D89-1D8C-4965-BE40-2E1BF3695F74Q41195708-68BFA167-1BD7-44A8-9376-61305D4E85C3
P2860
Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Evaluation of clinically trans ...... c mouse model of neuroblastoma
@ast
Evaluation of clinically trans ...... c mouse model of neuroblastoma
@en
Evaluation of clinically trans ...... c mouse model of neuroblastoma
@nl
type
label
Evaluation of clinically trans ...... c mouse model of neuroblastoma
@ast
Evaluation of clinically trans ...... c mouse model of neuroblastoma
@en
Evaluation of clinically trans ...... c mouse model of neuroblastoma
@nl
prefLabel
Evaluation of clinically trans ...... c mouse model of neuroblastoma
@ast
Evaluation of clinically trans ...... c mouse model of neuroblastoma
@en
Evaluation of clinically trans ...... c mouse model of neuroblastoma
@nl
P2093
P2860
P50
P356
P1433
P1476
Evaluation of clinically trans ...... c mouse model of neuroblastoma
@en
P2093
Albert Hallsworth
Andrew D J Pearson
Chris Jones
Elizabeth R Tucker
Hannah Webber
Jessica K R Boult
Lauren C J Baker
Lynsey Vaughan
Sergey Popov
P2860
P304
P356
10.1148/RADIOL.12120128
P407
P577
2012-11-20T00:00:00Z